0A9G Stock Chart & Stats
$0.32
>-$0.01(-0.87%)
At close: 4:00 PM EDT
$0.32
>-$0.01(-0.87%)
Day’s Range― - ―
52-Week Range$0.22 - $2.36
Previous CloseN/A
Volume14.20K
Average Volume (3M)83.86K
Market Cap
$48.35M
Enterprise Value$21.97
Total Cash (Recent Filing)$30.12M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume69,824
30 Day Avg. Volume83,855
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside837.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$2.37M
Bulls Say, Bears Say
Bulls Say
Alvelestat Sentynl Option And LicenseThe Sentynl option transforms alvelestat into a capital‑light value driver: a non‑refundable fee, potential $40M upfront/R&D payments and future royalties shift late‑stage funding risk to a partner while preserving upside, improving long‑term funding optionality for clinical execution.
Low Reported Debt Versus EquityA low debt load provides enduring financial flexibility for a cash‑burning biotech: limited interest burden reduces solvency risk and preserves options for equity or partnership financing, making the company less vulnerable to adverse credit conditions during multi‑year clinical programs.
Clinical Positioning: First‑in‑class AATD‑LD And Phase 3 LeadershipLeading the global Phase 3 and active regulatory engagement signal program control and strategic value capture: being positioned for a potential first‑in‑class oral therapy in a defined rare disease market builds durable commercial optionality and partner interest through late‑stage proof points.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow underscores ongoing reliance on external financing or partner payments to fund development. Over months to years this elevates dilution or deal‑dependency risk and constrains discretionary investment in pipelines or commercialization preparation.
Effectively Zero TTM Revenue And Large Net LossesNear‑zero revenue and persistent material losses reflect a classic clinical‑stage biotech profile with no self‑funding capability. Over the medium term this limits reinvestment capacity, increases reliance on partners or equity raises, and raises execution risk if milestones slip.
Declining Asset Base Reduces Financial FlexibilityA shrinking asset base materially weakens balance‑sheet resilience and reduces collateral or buffer for future financings. Combined with ongoing cash burn, this structural decline increases the probability of dilutive equity issuance or onerous partnership terms to sustain multi‑year clinical programs.
Mereo Biopharma Group Plc News
0A9G FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest share price was $0.22 and its highest was $2.36 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $48.35M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 95 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went up 22.968%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in GB:0A9G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (837.50% Upside)
$3.00 (837.50% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
0A9G Stock 12 Month Forecast
Average Price Target
$3.00
▲(837.50% Upside)